Efficacy and Cardiovascular Safety of Thiazolidinediones

Author(s): Arkiath Veettil Raveendran*, Cornelius James Fernandez, Koshy Jacob

Journal Name: Current Drug Safety

Volume 16 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Type 2 diabetes mellitus (T2DM) is characterized by a progressive beta cell dysfunction in the setting of peripheral insulin resistance. Insulin resistance in subjects with type 2 diabetes and metabolic syndrome is primarily caused by an ectopic fat accumulation in the liver and skeletal muscle. Insulin sensitizers are particularly important in the management of T2DM. Though thiazolidinediones (TZDs) are principally insulin sensitizers, they possess an ability to preserve pancreatic β-cell function and thereby exhibit durable glycemic control. Cardiovascular outcome trials (CVOTs) have shown that Glucagon-like-peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose transporter-2 inhibitors (SGLT2i) have proven cardiovascular safety. In this era of CVOTs, drugs with proven cardiovascular (CV) safety are often preferred in patients with preexisting cardiovascular disease or at risk of cardiovascular disease. In this review, we will describe the three available drugs belonging to the TZD family, with special emphasis on their efficacy and CV safety.

Keywords: Pioglitazone, rosiglitazone, glycemic control, heart failure, cardiovascular disease, insulin resistance.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2021
Published on: 26 October, 2020
Page: [233 - 249]
Pages: 17
DOI: 10.2174/1574886315666201026125530
Price: $65

Article Metrics

PDF: 445
HTML: 3